Eli Lilly Leverages AI to Transform Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 15 2026
0mins
Source: Fool
- AI Platform Launch: Eli Lilly launched the TuneLab platform in September last year, allowing other drugmakers digital access to proprietary data on drug molecule performance, which saves significant time and money, enabling companies to focus on their best research projects.
- Major Investment Partnership: Eli Lilly partnered with Nvidia, committing $1 billion to build a supercomputer aimed at deepening disease understanding and advancing drug development, marking a significant step in the company's AI drug development efforts.
- Huge Market Potential: According to Straits Research, the AI-powered drug discovery industry is expected to grow at an annual rate of 30% through 2034, reaching over $20 billion, providing Eli Lilly with substantial future revenue opportunities.
- Increased Collaboration Opportunities: By owning a powerful drug development platform, Eli Lilly can not only optimize its own research but also establish partnerships with smaller pharmaceutical companies, helping them bring new drugs to market and enhancing its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1041.650
Low
950.00
Averages
1192
High
1500
Current: 1041.650
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Wegovy Recommended for EU Approval as First Oral Weight-Loss Drug
- Intensifying Market Competition: Novo Nordisk's weight-loss pill Wegovy has received a recommendation for approval from the European Medicines Agency, becoming the first oral weight-loss drug in Europe, highlighting intensified competition with U.S. rival Eli Lilly as the obesity drug market is projected to reach $150 billion in the next decade.
- Significant Clinical Trial Results: In a late-stage study, patients taking the 25-milligram Wegovy pill lost an average of 16.6% of their body weight compared to just 2.7% for the placebo group, demonstrating the drug's effectiveness in weight loss, which may attract more patients to oral treatments.
- Market Expansion Potential: Following its U.S. launch, Wegovy gained an early market advantage after FDA approval, while Lilly's weight-loss pill Zepbound was also launched in April, indicating that oral treatments could draw in new patients and drive market expansion rather than merely switching users from injections.
- Regulatory Review Process: The EMA's recommendation will be reviewed by the European Commission for marketing authorization, with expectations that the regulatory review of this new generation of weight-loss pills will conclude this summer, further advancing Novo Nordisk's market positioning.
See More
Eli Lilly Showcases New Therapy Data at ASCO Meeting
- Clinical Trial Results: Eli Lilly's Phase 3 LIBRETTO-432 study demonstrates significant event-free survival outcomes for Retevmo (selpercatinib) in RET fusion-positive NSCLC patients, likely enhancing the drug's market acceptance and sales growth.
- New Drug Presentation: Verzenio (abemaciclib) has been selected for a Plenary Session presentation in the Phase 3 SARC041 study for patients with advanced dedifferentiated liposarcoma, indicating Lilly's ongoing innovation and exploration of new indications in cancer treatment.
- Acquisition Progress: Lilly has agreed to acquire Kelonia Therapeutics, which will present updated data on its BCMA-targeted CAR-T therapy for relapsed multiple myeloma at the conference, further strengthening Lilly's competitive position in cell therapy.
- Diverse Investments: Lilly will also showcase initial clinical results for an investigational ADC targeting Nectin-4, highlighting its potential in treating various cancers and reflecting the company's broad investment and commitment to oncology research and development.
See More
GLP-1 Drugs Show Promise for Cancer Patient Outcomes
- Cancer Patient Benefits: Recent studies suggest that patients using GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro experience significantly reduced tumor progression, particularly among early-stage cancer patients, indicating improved survival rates and lower recurrence risks.
- Supporting Research Data: A study from the Cleveland Clinic tracked over 10,000 early-stage cancer patients, revealing that GLP-1 users had a cancer spread rate of only 10%, compared to 22% in the control group, demonstrating the drugs' significant advantages in controlling cancer progression.
- Breast Cancer Survival Rates: An analysis from the University of Texas MD Anderson Cancer Center found that over 95% of GLP-1 users were alive five years post-diagnosis, while non-users had a survival rate of only 89.5%, further emphasizing the potential long-term benefits of GLP-1 drugs.
- Significant Market Impact: The health benefits of GLP-1 drugs extend beyond blood sugar reduction and weight loss to include lower risks of heart attacks and strokes, positioning Novo Nordisk and Eli Lilly as two of the world's most valuable pharmaceutical companies, likely attracting further investment.
See More
Hims Launches Generic Semaglutide in Canada
- Market Access: Hims has launched generic Semaglutide in Canada at C$149 per month, significantly lower than the C$200-C$400 range for branded Ozempic, which is expected to attract a large number of cost-conscious patients and expand market share.
- Patent Expiration Impact: Novo Nordisk's failure to pay a C$250 patent maintenance fee led to the early expiration of its Semaglutide patent, allowing Hims to quickly enter the competitive GLP-1 market, thereby enhancing its market competitiveness.
- Product Portfolio Expansion: The generic drug offered by Hims is manufactured by Apotex, marking the company's first international rollout, while also providing branded GLP-1 drugs through a partnership with Novo Nordisk, further enriching its product line.
- Intensifying Industry Competition: With Lilly's new drug Retatrutide showing an average weight loss of 28.3% in clinical data, Hims' market strategy will face increased pressure, necessitating continuous innovation to maintain its competitive edge.
See More
Eli Lilly's Obesity Therapy Trial Shows Significant Results
- Significant Weight Loss: Eli Lilly's next-gen obesity therapy retatrutide achieved an average weight loss of up to 28% over 80 weeks in trials, indicating strong potential in the obesity treatment market, which could significantly enhance the company's competitive edge.
- Competitive Comparison: The therapy's efficacy surpasses Lilly's own tirzepatide and Novo Nordisk's semaglutide, highlighting its leading position in the emerging obesity treatment market and potentially attracting more patients to choose this product.
- Safety and Tolerability: Although 11% of patients discontinued treatment at the highest 12 mg dose due to adverse events, the overall tolerability profile is consistent with other gut-hormone-based therapies, which may improve patient acceptance upon future commercialization.
- Analyst Optimism: BMO Capital Markets analysts noted the significantly improved discontinuation rate of retatrutide, likely boosting its market acceptance, while Citi analysts praised the data showing a 30% average weight loss in severely obese patients at the highest dose, describing it as unprecedented efficacy.
See More
Market Trends and Company Earnings Insights
- Oil and Treasury Yields: U.S. benchmark WTI crude prices have surged back above $100 per barrel, with the 10-year Treasury yield hovering around 4.6%, leading to lower stock futures this morning, reflecting market concerns over inflation and rising interest rates that could dampen investor confidence.
- Nvidia Buyback Plan: Nvidia has added $80 billion to its stock buyback authorization, on top of the existing $39 billion, and increased its annual dividend payout from $0.04 to $1, indicating a strong commitment to shareholder returns, although the market reaction has been muted, this could bolster investor confidence in the long run.
- Walmart's Earnings Outlook: Walmart is feeling the pinch from high gas prices, resulting in a disappointing earnings outlook despite matching earnings and beating revenue expectations in Q1, with shares down approximately 2.5%, reflecting cautious sentiment regarding future growth prospects.
- Inflation Rollback: Kroger CEO Greg Foran announced plans for the largest price cuts in years to stay competitive, although shares fell about 4% following the news, this strategic move could enhance market share and customer loyalty over time.
See More
Novo Nordisk's Wegovy Recommended for EU Approval as First Oral Weight-Loss Drug
- Intensifying Market Competition: Novo Nordisk's weight-loss pill Wegovy has received a recommendation for approval from the European Medicines Agency, becoming the first oral weight-loss drug in Europe, highlighting intensified competition with U.S. rival Eli Lilly as the obesity drug market is projected to reach $150 billion in the next decade.
- Significant Clinical Trial Results: In a late-stage study, patients taking the 25-milligram Wegovy pill lost an average of 16.6% of their body weight compared to just 2.7% for the placebo group, demonstrating the drug's effectiveness in weight loss, which may attract more patients to oral treatments.
- Market Expansion Potential: Following its U.S. launch, Wegovy gained an early market advantage after FDA approval, while Lilly's weight-loss pill Zepbound was also launched in April, indicating that oral treatments could draw in new patients and drive market expansion rather than merely switching users from injections.
- Regulatory Review Process: The EMA's recommendation will be reviewed by the European Commission for marketing authorization, with expectations that the regulatory review of this new generation of weight-loss pills will conclude this summer, further advancing Novo Nordisk's market positioning.
See More
Eli Lilly Showcases New Therapy Data at ASCO Meeting
- Clinical Trial Results: Eli Lilly's Phase 3 LIBRETTO-432 study demonstrates significant event-free survival outcomes for Retevmo (selpercatinib) in RET fusion-positive NSCLC patients, likely enhancing the drug's market acceptance and sales growth.
- New Drug Presentation: Verzenio (abemaciclib) has been selected for a Plenary Session presentation in the Phase 3 SARC041 study for patients with advanced dedifferentiated liposarcoma, indicating Lilly's ongoing innovation and exploration of new indications in cancer treatment.
- Acquisition Progress: Lilly has agreed to acquire Kelonia Therapeutics, which will present updated data on its BCMA-targeted CAR-T therapy for relapsed multiple myeloma at the conference, further strengthening Lilly's competitive position in cell therapy.
- Diverse Investments: Lilly will also showcase initial clinical results for an investigational ADC targeting Nectin-4, highlighting its potential in treating various cancers and reflecting the company's broad investment and commitment to oncology research and development.
See More
GLP-1 Drugs Show Promise for Cancer Patient Outcomes
- Cancer Patient Benefits: Recent studies suggest that patients using GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro experience significantly reduced tumor progression, particularly among early-stage cancer patients, indicating improved survival rates and lower recurrence risks.
- Supporting Research Data: A study from the Cleveland Clinic tracked over 10,000 early-stage cancer patients, revealing that GLP-1 users had a cancer spread rate of only 10%, compared to 22% in the control group, demonstrating the drugs' significant advantages in controlling cancer progression.
- Breast Cancer Survival Rates: An analysis from the University of Texas MD Anderson Cancer Center found that over 95% of GLP-1 users were alive five years post-diagnosis, while non-users had a survival rate of only 89.5%, further emphasizing the potential long-term benefits of GLP-1 drugs.
- Significant Market Impact: The health benefits of GLP-1 drugs extend beyond blood sugar reduction and weight loss to include lower risks of heart attacks and strokes, positioning Novo Nordisk and Eli Lilly as two of the world's most valuable pharmaceutical companies, likely attracting further investment.
See More
Hims Launches Generic Semaglutide in Canada
- Market Access: Hims has launched generic Semaglutide in Canada at C$149 per month, significantly lower than the C$200-C$400 range for branded Ozempic, which is expected to attract a large number of cost-conscious patients and expand market share.
- Patent Expiration Impact: Novo Nordisk's failure to pay a C$250 patent maintenance fee led to the early expiration of its Semaglutide patent, allowing Hims to quickly enter the competitive GLP-1 market, thereby enhancing its market competitiveness.
- Product Portfolio Expansion: The generic drug offered by Hims is manufactured by Apotex, marking the company's first international rollout, while also providing branded GLP-1 drugs through a partnership with Novo Nordisk, further enriching its product line.
- Intensifying Industry Competition: With Lilly's new drug Retatrutide showing an average weight loss of 28.3% in clinical data, Hims' market strategy will face increased pressure, necessitating continuous innovation to maintain its competitive edge.
See More
Eli Lilly's Obesity Therapy Trial Shows Significant Results
- Significant Weight Loss: Eli Lilly's next-gen obesity therapy retatrutide achieved an average weight loss of up to 28% over 80 weeks in trials, indicating strong potential in the obesity treatment market, which could significantly enhance the company's competitive edge.
- Competitive Comparison: The therapy's efficacy surpasses Lilly's own tirzepatide and Novo Nordisk's semaglutide, highlighting its leading position in the emerging obesity treatment market and potentially attracting more patients to choose this product.
- Safety and Tolerability: Although 11% of patients discontinued treatment at the highest 12 mg dose due to adverse events, the overall tolerability profile is consistent with other gut-hormone-based therapies, which may improve patient acceptance upon future commercialization.
- Analyst Optimism: BMO Capital Markets analysts noted the significantly improved discontinuation rate of retatrutide, likely boosting its market acceptance, while Citi analysts praised the data showing a 30% average weight loss in severely obese patients at the highest dose, describing it as unprecedented efficacy.
See More
Market Trends and Company Earnings Insights
- Oil and Treasury Yields: U.S. benchmark WTI crude prices have surged back above $100 per barrel, with the 10-year Treasury yield hovering around 4.6%, leading to lower stock futures this morning, reflecting market concerns over inflation and rising interest rates that could dampen investor confidence.
- Nvidia Buyback Plan: Nvidia has added $80 billion to its stock buyback authorization, on top of the existing $39 billion, and increased its annual dividend payout from $0.04 to $1, indicating a strong commitment to shareholder returns, although the market reaction has been muted, this could bolster investor confidence in the long run.
- Walmart's Earnings Outlook: Walmart is feeling the pinch from high gas prices, resulting in a disappointing earnings outlook despite matching earnings and beating revenue expectations in Q1, with shares down approximately 2.5%, reflecting cautious sentiment regarding future growth prospects.
- Inflation Rollback: Kroger CEO Greg Foran announced plans for the largest price cuts in years to stay competitive, although shares fell about 4% following the news, this strategic move could enhance market share and customer loyalty over time.
See More
